What is the difference between hormone receptor positive and triple negative breast cancer

Understanding Hormone Receptor-Positive vs. Triple-Negative Breast Cancer

These are two distinct types of breast cancer based on what proteins are found on the cancer cells. Let me explain the key differences:

Hormone Receptor-Positive (HR+) Breast Cancer

According to the NCCN Guidelines, hormone receptor-positive breast cancer means the cancer cells have receptors for estrogen (ER+), progesterone (PR+), or both. Here's what this means:

How it works:

• Estrogen receptors (ER) are stimulated by estrogen and provide survival and growth signals to cancer cells
• Progesterone receptors (PR) bind progesterone and also provide survival signals
• When hormones attach to these receptors inside breast cancer cells, they can cause the cancer to grow

Testing criteria:

• A cancer is considered ER+ if testing finds estrogen hormone receptors in at least 1 out of every 100 cancer cells
• Both ER and PR need to be negative for the cancer to be considered hormone receptor-negative (HR-)

Treatment advantage: HR+ breast cancers can be treated with endocrine therapy (also called hormone therapy), which either blocks estrogen receptor signaling or decreases estrogen production in the body. This gives patients an important targeted treatment option.

Triple-Negative Breast Cancer

Triple-negative breast cancer means the cancer cells test negative for all three key receptors:

• Estrogen receptor-negative (ER-)
• Progesterone receptor-negative (PR-)
• HER2-negative (doesn't make too much of the HER2 protein)

Key characteristics:

• These cancers don't have the hormone receptors that fuel HR+ cancers
• They also don't overproduce HER2 protein
• According to NCCN Guidelines, HR- cancers often grow faster than HR+ cancers
• They cannot be treated with endocrine therapy or HER2-targeted therapies

Why This Matters for Treatment

The American Cancer Society and NCCN emphasize that knowing your cancer's receptor status is crucial because:

1. HR+ cancers respond to endocrine therapies that block hormones
2. Triple-negative cancers require different approaches, typically chemotherapy and sometimes immunotherapy
3. Treatment is personalized based on these biomarkers

Both types can occur in inflammatory breast cancer (IBC), and as the NCCN Guidelines note: "IBC can vary in its expression of these receptors and is not confined to one subtype of breast cancer."

Important: Your pathology report will include your specific receptor status, which your care team uses to create your personalized treatment plan. Always discuss your specific results with your oncologist to understand what they mean for your individual situation.